PMC:7228307 / 24380-24962
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
432 | 100-104 | Gene | denotes | FcγR | Gene:2213 |
433 | 348-354 | Chemical | denotes | glycan | MESH:D011134 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T248 | 125-138 | Body_part | denotes | cell membrane | http://purl.org/sig/ont/fma/fma63841 |
T249 | 125-129 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T468 | 48-50 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T469 | 100-102 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T470 | 105-117 | http://purl.obolibrary.org/obo/OBI_0000245 | denotes | organization |
T471 | 125-129 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T472 | 130-138 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
T473 | 326-328 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T474 | 362-363 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T475 | 529-531 | http://purl.obolibrary.org/obo/CLO_0001302 | denotes | 34 |
T476 | 544-546 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T125 | 329-340 | Chemical | denotes | polypeptide | http://purl.obolibrary.org/obo/CHEBI_15841 |
T126 | 452-463 | Chemical | denotes | application | http://purl.obolibrary.org/obo/CHEBI_33232 |
T127 | 512-520 | Chemical | denotes | effector | http://purl.obolibrary.org/obo/CHEBI_35224 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T143 | 105-117 | http://purl.obolibrary.org/obo/OBI_0100026 | denotes | organization |
T144 | 125-129 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cell |
T145 | 369-377 | http://purl.obolibrary.org/obo/BFO_0000034 | denotes | function |
T146 | 571-581 | http://purl.obolibrary.org/obo/IDO_0000607 | denotes | productive |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T27 | 329-340 | Chemical | denotes | polypeptide | http://purl.obolibrary.org/obo/CHEBI_15841 |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
432 | 100-104 | Gene | denotes | FcγR | Gene:2213 |
433 | 348-354 | Chemical | denotes | glycan | MESH:D011134 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T141 | 0-244 | Sentence | denotes | Clearly, the effects of immune complex valency, Fc density, presentation and geometry together with FcγR organization in the cell membrane suggest that the development of mAbs to certain targets will be heavily influenced by the context of use. |
T142 | 245-361 | Sentence | denotes | Thus, improved mAb potency may not necessarily be achieved by engineering of the Fc polypeptide or its glycan alone. |
T143 | 362-582 | Sentence | denotes | A more function‐oriented approach early in mAb selection and development by, for example, application of rapid screening technologies that select for effector potency,34 followed by Fc engineering may be more productive. |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T247 | 125-138 | Body_part | denotes | cell membrane | http://purl.org/sig/ont/fma/fma63841 |
T248 | 125-129 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T141 | 0-244 | Sentence | denotes | Clearly, the effects of immune complex valency, Fc density, presentation and geometry together with FcγR organization in the cell membrane suggest that the development of mAbs to certain targets will be heavily influenced by the context of use. |
T142 | 245-361 | Sentence | denotes | Thus, improved mAb potency may not necessarily be achieved by engineering of the Fc polypeptide or its glycan alone. |
T143 | 362-582 | Sentence | denotes | A more function‐oriented approach early in mAb selection and development by, for example, application of rapid screening technologies that select for effector potency,34 followed by Fc engineering may be more productive. |